FDA Allows Resumption Of Lupus Trials With Epratuzumab
Thu, 16 Nov 2006 08:00 AM EST
... Immunomedics, Inc. (Nasdaq: IMMU), a biopharmaceutical company focused on developing therapeutic monoclonal antibodies, today announced that their partner, UCB (Euronext Brussels: UCB), has received notification from FDA that the clinical hold on existing trials with epratuzumab in patients with lupus has been lifted. [click link for full article] ...
Related Topics
- Lupus
- Lupus Anticoagulant
- Systemic Lupus Erythematosus
- Lupus Nephritis
- Clinical Trials
- Tacrolimus ointment
- Mammography
- Systemic Lupus Erythematosus/sle
- Carcinogens
- Systemic Lupus
- Lupus anticoagulants
- Cutaneous Lupus Erythematosus
- Lupus - Neurological Sequelae
- Neurological Sequelae Of Lupus
- Drug-induced lupus erythematosus
- Pimecrolimus Cream 1%
- Dietary Guidelines
- Thalidomide
- Cartilage Disorders
- Pediatric Aids

Not Signed In -

